141 related articles for article (PubMed ID: 35321889)
1. Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.
Sivakumaran T; Krasovitsky M; Freimund A; Lee YC; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G
Int J Gynecol Cancer; 2022 Jul; 32(7):906-912. PubMed ID: 35321889
[TBL] [Abstract][Full Text] [Related]
2. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD; Wang H; Sriram B; Khan A; Senter L; McLaughlin EM; Bixel KL; Chambers LM; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Backes FJ
Gynecol Oncol; 2024 Mar; 182():51-56. PubMed ID: 38262238
[TBL] [Abstract][Full Text] [Related]
3. Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.
Pan YE; Hood A; Ahmad H; Altwerger G
Ann Pharmacother; 2023 Oct; 57(10):1162-1171. PubMed ID: 36651235
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study.
Schlootz S; Saner FAM; Rabaglio M; Imboden S; Wampfler J
Swiss Med Wkly; 2024 Apr; 154():3386. PubMed ID: 38754016
[TBL] [Abstract][Full Text] [Related]
5. Targeting BRCA and PALB2 in Pancreatic Cancer.
Anbil S; Reiss KA
Curr Treat Options Oncol; 2024 Mar; 25(3):346-363. PubMed ID: 38311708
[TBL] [Abstract][Full Text] [Related]
6. The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer.
Molnár S; Beke L; Méhes G; Póka R
Pathol Oncol Res; 2020 Oct; 26(4):2549-2555. PubMed ID: 32594311
[TBL] [Abstract][Full Text] [Related]
7. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Scott CL; Swisher EM; Kaufmann SH
J Clin Oncol; 2015 Apr; 33(12):1397-406. PubMed ID: 25779564
[TBL] [Abstract][Full Text] [Related]
8. Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer.
Zhu M; Wang J; Wuna Y; Wang Y; Li H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 46(6):644-652. PubMed ID: 34275934
[TBL] [Abstract][Full Text] [Related]
9. Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.
Wu X; Liu J; Wang J; Wang L; Lin Z; Wang X; Zhu J; Kong B; Fei J; Tang Y; Xia B; Liang Z; Wang K; Huang Y; Zheng H; Lin A; Jiang K; Wang W; Wang X; Lou G; Pan H; Yao S; Li G; Hao M; Cai Y; Chen X; Yang Z; Chen Y; Wen H; Qu P; Xu C; Hsieh CY;
Nat Med; 2024 May; ():. PubMed ID: 38750351
[TBL] [Abstract][Full Text] [Related]
10. Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT).
Kobayashi Y; Shimada M; Tamate M; Cho HW; Zhu J; Chou HH; Kajiyama H; Okamoto A; Aoki D; Kang S; Lee JW; Kim JW; Kim JH; Lin Z; Liu J; Wu X; Lai HC; Chang TC; Lai CH; Kim YM; Enomoto T
J Gynecol Oncol; 2024 May; 35(3):e87. PubMed ID: 38606827
[TBL] [Abstract][Full Text] [Related]
11. Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey.
Kim JH; Lee Y; Kim DY; Kim S; Seo SS; Kang S; Park SY; Lim MC
J Gynecol Oncol; 2024 Jan; 35(1):e3. PubMed ID: 37681357
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study.
Xu Y; Xiong F; Li H; Zheng H; Jiang J; Li Q; Li G; Zhao W; Li R; Li J; Xie R; An R; Zhang H; Gao Q
Int J Gynecol Cancer; 2024 Apr; ():. PubMed ID: 38658024
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer progressed after prior poly (adenosine diphosphate-ribose) polymerase inhibitors: A retrospective cohort study.
Zhao Y; Yuan H; Chen Y; Yao H; Li N; Wu L; Yuan G
Eur J Surg Oncol; 2024 May; 50(7):108383. PubMed ID: 38704898
[TBL] [Abstract][Full Text] [Related]
14. Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study.
Shao C; Ren Y; Zhou H; Lee LC; Chen C; Dettman EJ; Cristescu R; Gozman A; Jin F; Zhou W
Adv Ther; 2024 Feb; 41(2):759-776. PubMed ID: 38169059
[TBL] [Abstract][Full Text] [Related]
15. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Corbaux P; You B; Glasspool RM; Yanaihara N; Tinker AV; Lindemann K; Ray-Coquard IL; Mirza MR; Subtil F; Colomban O; Péron J; Karamouza E; McNeish I; Kelly C; Kagimura T; Welch S; Lewsley LA; Paoletti X; Cook A
Eur J Cancer; 2023 Sep; 191():112966. PubMed ID: 37542936
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations.
Doroshow DB; O'Donnell PH; Hoffman-Censits JH; Gupta SV; Vaishampayan U; Heath EI; Garcia P; Zhao Q; Yu M; Milowsky MI; Galsky MD
JCO Precis Oncol; 2023 Jul; 7():e2300095. PubMed ID: 37410974
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with
Lee YJ; Shin YK; Kim NR; Kim SI; Lee YY; Park JY; Kim JW; Cho HW; Lee JY
J Gynecol Oncol; 2024 Mar; ():. PubMed ID: 38551024
[TBL] [Abstract][Full Text] [Related]
18. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Kurnit KC; Fleming GF; Lengyel E
Obstet Gynecol; 2021 Jan; 137(1):108-121. PubMed ID: 33278287
[TBL] [Abstract][Full Text] [Related]
19. Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care.
Norell CH; Butler J; Farrell R; Altman A; Bentley J; Cabasag CJ; Cohen PA; Fegan S; Fung-Kee-Fung M; Gourley C; Hacker NF; Hanna L; Høgdall CK; Kristensen G; Kwon J; McNally O; Nelson G; Nordin A; O'Donnell D; Schnack T; Sykes PH; Zotow E; Harrison S
Int J Gynecol Cancer; 2020 Nov; 30(11):1748-1756. PubMed ID: 32784203
[TBL] [Abstract][Full Text] [Related]
20. A case of hereditary breast and ovarian cancer syndrome of initially presented as cancer of unknown primary with lymph node metastases unveiled by genetic analysis.
Yamada J; Fukuda K; Sugawara T; Makino K; Shimazu K; Yoshida T; Taguchi D; Shinozaki H; Terada Y; Nanjo H; Shibata H
Int Cancer Conf J; 2024 Apr; 13(2):139-143. PubMed ID: 38524651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
